Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- MOH +2.3% ( sees Q2 EPS below consensus; lowers FY25 guidance).
M&A news:
- WNS +14.1% (Capgemini to acquire WNS for $76.50/share).
Other news:
-
APGE +18.7% (announces positive 16-week data from phase 2 APEX clinical trial of APG777, its potentially best-in-class Anti-IL-13 antibody, in moderate-to-severe atopic dermatitis ).
-
COGT +18.7% (announces "positive" top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis demonstrating clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden).
-
KALV +12.9% (announces FDA approval of EKTERLY, first and only oral on-demand treatment for hereditary angioedema).
-
SAND +9.6% (enters into definitive agreement with Royal Gold Inc. (RGLD) in which Royal Gold will acquire SAND in an all-share transaction with an implied value of approximately $3.5 bln ).
-
IREN +4.5% (publishes its monthly update for June 2025).
-
LXEO +4.5% (announces that the U.S. Food and Drug administration has granted Breakthrough Therapy designation to LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich ataxia)
-
RKLB +3.9% (Barron's out positive on RKLB).
-
AEMD +3.2% ( Hemopurifier to Enhance Anti-PD1 Therapy; Assuming Coverage With Neutral Rating and $1.50 PT -- H.C. Wainwright).
-
LGIH +2.8% (announced it closed 457 homes in June 2025 and closed 1,323 homes in the second quarter of 2025).
-
DNLI +2.1% (FDA accepts BLA for review seeking accelerated approval for tividenofusp alfa for Hunter syndrome ).
-
AZN +1% ( Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer).
- OGN +1% (announces that VTAMA cream, 1%, was granted a strong recommendation by the American Academy of Dermatology in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis).